Drugs / Recombinant fragment of human surfactant protein D
Recombinant fragment of human surfactant protein D
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05898633 | Apr 2024 → Dec 2025 | bronchopulmonary dysplasia, respiratory distress syndrome in premature infants | University College, London | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant fragment of human surfactant protein D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05898633 ↗ |
| Modality | Protein / enzyme biologic | “RESPONSE uses a recombinant fragment of human SP D (rfhSP-D)” PMID 39153779 ↗ Aug 2024 |
| Route | Other | “participants will receive three doses of rfhSP-D via endotracheal route” PMID 39153779 ↗ Aug 2024 |